Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Immunotherapy of metastatic non-small cell lung cancer from first line to resistance and its management].

Bulletin du cancer - 1 Jan 2000

Basse Clémence, Swalduz Aurelie, Levra Matteo Giaj, Girard Nicolas, Remon Jordi, Moro-Sibilot Denis

Abstract excerpt

Immunotherapy alone or in combination with chemotherapy is now an integral part of the treatment of metastatic NSCLC. This treatment is transforming the management of these cancers, with 20-30% of patients achieving long survival. However, disease progression under treatment is still the rule for the majority of patients, raising problems both in understanding its mechanisms and in subsequent appropriate...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anaplastic Lymphoma Kinase
Share to Antibodies, Monoclonal, Humanized

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Clinical Trials, Phase III as Topic

Share to Combined Modality Therapy

Share to Genes, erbB-1

Share to Immunotherapy

Share to Immunotherapy, Adoptive

Share to Receptors, Chimeric Antigen

Source

Identifiers

PMID: 32532420
DOI: 10.1016/j.bulcan.2020.04.018

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Immunotherapy of metastatic non-small cell lung cancer from first line to resistance and its management].PMID 32532420Read ↗

[Molecular mechanisms of targeted drug resistance in lung cancer and its therapeutic strategy].Semantic proximity Read ↗

[Advances in research on primary resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer patients].Semantic proximity Read ↗

[Research progress of the resistance mechanism of non-small cell lung cancer to EGFR-TKIs].Semantic proximity Read ↗

Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations-a review.Semantic proximity Read ↗

Drug Resistance and Its Significance for Treatment Decisions in Non-Small-Cell Lung CancerSemantic proximity Read ↗

[Resistances to targeted therapies and strategy for following therapeutic lines in metastatic NSCLC].Semantic proximity Read ↗

Personalized therapy for lung cancer: striking a moving target.Semantic proximity Read ↗

[Precision treatment after resistance to first-generation EGFR-TKI in patients with non-small cell lung cancer].Semantic proximity Read ↗

Current Strategies for Treating NSCLC: From Biological Mechanisms to Clinical TreatmentSemantic proximity Read ↗

Immunotherapy in EGFR-TKI-resistant NSCLC: Mechanisms, therapeutic strategies, and emerging challenges.Semantic proximity Read ↗

Immunotherapy in Advanced NSCLC Without Driver Mutations: Available Therapeutic Alternatives After Progression and Future Treatment Options.Semantic proximity Read ↗

[Targeted Therapy and Mechanism of Drug Resistance in Non-small Cell Lung Cancer with Epidermal Growth Factor Receptor Gene Mutation].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.